Table 5. Antibiogram resultsa from pathogens identified from central line-associated bloodstream infections, 2017–2021.
| Antibiotic | Number of resistant/number tested and % | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-positive | Gram-negative | Fungi | ||||||||||||||
| Coagulase-negative staphylococcib | S. aureusc | Enterococcus spp. | Klebsiella spp. | E. coli | Enterobacter spp. | C. albicans | Candida spp. otherd | |||||||||
| # resistant/# tested | % | # resistant/# tested | % | # resistant/# tested | % | # resistant/# tested | % | # resistant/# tested | % | # resistant/# tested | % | # resistant/# tested | % | # resistant/# tested | % | |
| Ampicillin | 16/17 | 94 | N/A | N/A | 130/350 | 37 | 99/99 | 100 | 67/95 | 71 | 55/59 | 93 | N/A | N/A | N/A | N/A |
| Cefazolin | 147/176 | 84 | 18/119 | 15 | N/A | N/A | 33/81 | 41 | 27/79 | 34 | 48/48 | 100 | N/A | N/A | N/A | N/A |
| Ceftriaxone | 9/10 | 90 | 3/6 | 50 | N/A | N/A | 19/86 | 22 | 18/78 | 23 | 33/59 | 56 | N/A | N/A | N/A | N/A |
| Clindamycin | 108/146 | 74 | 33/116 | 28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Ciprofloxacin | 4/11 | 36 | N/A | N/A | 10/19 | 53 | 10/85 | 12 | 27/66 | 41 | 1/74 | 1 | N/A | N/A | N/A | N/A |
| Cloxacillin/oxacillin | 222/259 | 86 | 31/179 | 17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Erythromycin | 62/71 | 87 | 21/79 | 27 | 14/14 | 100 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gentamicine | 16/33 | 48 | 1/33 | 3 | 21/155 | 14 | 14/102 | 14 | 11/98 | 11 | 6/74 | 8 | N/A | N/A | N/A | N/A |
| Meropenem | 8/9 | 89 | N/A | N/A | N/A | N/A | 4/52 | 8 | 2/41 | 5 | 1/55 | 2 | N/A | N/A | N/A | N/A |
| Piperacillin-tazobactam | N/A | N/A | N/A | N/A | 3/11 | 22 | 12/80 | 15 | 16/82 | 20 | 21/60 | 35 | N/A | N/A | N/A | N/A |
| Penicillin | 56/57 | 98 | 41/48 | 85 | 19/40 | 48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Rifampin | 3/71 | 4 | 0/26 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Trimethoprim-sulfamethoxazole | 95/170 | 56 | 5/106 | 5 | N/A | N/A | 13/94 | 14 | 39/83 | 47 | N/A | N/A | N/A | N/A | N/A | N/A |
| Tobramycin | N/A | N/A | N/A | N/A | N/A | N/A | 8/81 | 10 | 8/80 | 10 | 3/60 | 5 | N/A | N/A | N/A | N/A |
| Vancomycin | 1/274 | 0 | 1/98 | 1 | 57/295 | 19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Amphotericin B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0/25 | 0 | 0/20 | 0 |
| Caspofungin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0/36 | 0 | 1/52 | 2 |
| Fluconazole | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1/99 | 1 | 19/89 | 21 |
Abbreviations: C. albicans, Candida albicans; E. coli, Escherichia coli; N/A, not available; S. aureus, Staphylococcus aureus
a Antibiotic/organism combinations with fewer than six tests were excluded
b Coagulase-negative staphylococci included S. lugdunensis, S. haemolyticus, S. epidermidis, S. capitis, S. hominis and S. warneri
c Included methicillin-susceptible S. aureus and methicillin-resistant S. aureus
d Other Candida spp. included C. dubliniensis, C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, and C. tropicalis
e Gentamicin synergy for gram-positive organisms